自然多纳米颗粒用于阿尔茨海默氏症疾病治疗
Peng Yang1,2, Qianqian Huang3, Jianhua Zhang1
1College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, China.
Advanced materials (Deerfield Beach, Fla.)
|November 27, 2023
概括
天然多纳米颗粒有效抑制粉样β聚合并逆转阿尔茨海默氏症.
科学领域:
- 纳米医学是一种纳米医学.
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 粉样β的异常积累是阿尔茨海默氏症 (AD) 病原发生的核心原因.
- 天然多显示出抑制粉样蛋白聚合的潜力,但其生物可用性较差,并通过血脑屏障 (BBB) 透.
- 现有的局限性阻碍了用于AD治疗的天然多的临床应用.
研究的目的:
- 开发一种用于制备天然多纳米颗粒的新方法.
- 评估这些纳米点在抑制粉样β聚合和治疗AD相关病理方面的疗效.
- 评估纳米点在阿尔茨海默病治疗中临床应用的潜力.
主要方法:
- 一个使用水性加热合成天然多纳米点的通用协议.
- 在体外评估amyloid-β纤维化抑制和纤维分裂.
- 在转基因阿尔茨海默病小鼠体内评估,包括认知测试和病理分析.
主要成果:
- 开发的纳米点有效抑制了粉样β纤维化,并促进了纤维分裂.
- 纳米颗粒减轻了粉样β斑块引起的损伤,包括氧化应激,微质激活,神经元损失和突触损伤.
- 在接受治疗的转基因小鼠中观察到识别和认知能力的显著改善;与小分子相比,纳米颗粒显示出增强的BBB透率和抗胺基因效应.
结论:
- 天然多纳米点为阿尔茨海默病提供了一个有前途的治疗策略.
- 这些纳米点克服了天然多的局限性,显示出更好的疗效和大脑透.
- 这种方法为开发有效的阿尔茨海默病治疗方法提供了一个可行的范例.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494


